Benvenuto su European Huntington's Disease Network
La nostra Missione
L’EHDN è un network indipendente e non profit dedicato alla promozione della ricerca, alla conduzione di trial clinici e al miglioramento delle cure destinate alle persone affette dalla Malattia di Huntington. Il network comprende clinici, ricercatori e persone affette dalla MH, insieme per realizzare la nostra missione. PER SAPERNE DI PIÙ SULL’EHDN
To receive the EHDN News via email, sign up for the EHDN newsletter at the bottom of this page↓
The EHDN community is deeply shocked and saddened by the tragic news of 7 November from Kraków – a beautiful and peaceful city that so warmly hosted our community for the EHDN Clinical Research Congress 22-24 October.
In Memoriam: Dr Ethan R. Signer (1937–2026)
We are profoundly saddened by the passing of Dr Ethan R. Signer, a pioneering molecular biologist and dedicated advocate for families impacted by Huntington’s disease (HD).
A founding scientist at CHDI Foundation (and before that, the Hereditary Disease Foundation), Ethan’s legacy extends beyond publications, programmes, and the many individuals he mentored to encompass the collective strength of our community today. His commitment to rigorous, collaborative science will live on in all of us as we continue our shared mission to advance HD research and care.
Ethan will be deeply missed by his family, friends, colleagues, collaborators, and the HD community.
Regulatory update: 2 November 2026 – uniQure announced FDA acceptance and priority review of the Biologics License Application with a target action date of 1 May 2027 for completing the review and issuing a decision.
On 29 September 2026, uniQure announced additional data from its ongoing phase 1/2 studies, comparing updated 36-month and 48-month outcomes with propensity score-matched external controls (Enroll-HD natural history dataset).
Disease progression, assessed using the composite Unified Huntington’s Disease Rating Scale, was slowed by 80% at 36 months (n = 15; nominally statistically significant) and 44% at 48 months (n = 12; not statistically significant). Disease progression was slowed significantly at both 36 and 48 months for Total Functional Capacity, a secondary endpoint. For the high-dose group, mean cerebrospinal fluid neurofilament light chain was 6% below baseline at 36 months (n = 14) and 4% above baseline at 48 months (n = 11).
The 36-month data from 12 participants who received the high dose (announced 24 September 2025) form the basis for the recent regulatory submissions. For details of all ongoing and completed EHDN-endorsed studies, click here.
We had an inspiring and productive time at the EHDN Clinical Research Congress 2026 in Kraków.
After meeting information and impressions like photos, abstracts and posters can be found here
.
The Lesley Jones Seed Fund was designed to help researchers fast-track the pilot studies needed to apply for larger funding elsewhere. Following the 100th award, as announced in the July issue of EHDN News, we are launching the Seed Fund Impact Survey to better understand the programme’s reach and impact since inception.
Past and current recipients are invited to share their input and insights so we can identify the most successful aspects of the programme, as well as areas that could be further refined and enhanced to better support the HD community. Seed fund projects that have generated significant impact will be featured as case studies in future issues of EHDN News and on our website.
The seventh release of the Enroll-HD periodic dataset, PDS7, has been fully curated and is now available.
PDS7 contains data from 30,511 Enroll-HD study participants encompassing 112,992 study visits, making it one of the largest cohort datasets available to researchers. Read more here.
Active EHDN endorsed* studies
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. ...
Alnylam Pharmaceuticals Global study endorsed* by EHDN
Study aims and goal: ALN-HTT02 is a novel C16-siRNA conjugate for huntingtin-lowering. This Phase Ib study aims to evaluate ALN-HTT02 in adults with Huntington’s Disease. No. of study participants and sites: The study plans to enrol participants from 2 sites in Australia and New Zealand. For further information see the clinical trial registration.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
Cardiff University DEVISE-HD study endorsed* by EHDN
Study aims and goal: Double-blind randomised controlled trial of sertraline, a selective serotonin reuptake inhibitor, to assess the feasibility of conducting a full-scale RCT of the efficacy of antidepressants in HD. The study will also assess some of the current clinical and methodological uncertainties around the effect of antidepressants on HD disease progression. No. of study participants and sites: 40 participants in the UK reporting mild or moderate symptoms of depression. For further information see here.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
Novartis Pharmaceuticals INVEST-HD study endorsed* by EHDN
Study aims and goal: Phase III study to investigate the efficacy, safety and tolerability of Votoplam in participants with Huntington’s Disease. No. of study participants and sites: It is planned to enrol 770 participants globally. The number of sites and countries is still to be determined. For further information see the clinical trial registration.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
FALCON-HD, sponsored by Skyhawk Therapeutics, Inc., endorsed* by EHDN
Study overview: Phase 2/3 randomised, double-blind, placebo-controlled clinical trial to evaluate the safety, pharmacodynamics and efficacy of SKY-0515 in HD. Recruitment: 400 participants will be recruited across Argentina, Brazil, Canada, Chile, Colombia, Georgia, Germany, Mexico, Peru, Poland, Spain, and the UK. For further information see the clinical trial registration and www.falcon-hd.com/study-information-worldwide.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
Vico Therapeutics B. V. study endorsed* by EHDN
Study aims and goal: The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington’s disease. No. of study participants and sites: The study plans to enrol participants from 14 sites in Denmark, France, Germany, Israel, Netherlands and United Kingdom. For further information see the clinical trial registration.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
uniQure Biopharma EU gene therapy study endorsed* by EHDN
Study aims and goal: Phase Ib/II Study to explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington Disease. No. of study participants and sites: The study aims to recruit 15 participants at several sites in the US and Europe. For further information see the clinical trial registration.
*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]
I ricercatori, i clinici e le famiglie con la MH lavorano insieme all’interno dell’EHDN per realizzare la nostra missione, e chiunque sia interessato alla MH può diventare un membro EHDN. Sono, inoltre, disponibili ulteriori informazioni sulla MH, sui siti clinici e sulla partecipazione a opportunità di ricerca più vicine a te, e su come rimanere in contatto con ulteriori risorse per te e la tua famiglia.
L’EHDN supporta la ricerca e il miglioramento della clinica per tutti gli stadi della MH, dalle basi e scienze applicate attraverso lo sviluppo di nuovi trattamenti, strumenti di valutazione clinica e linee guida per le migliori pratiche cliniche, alla valutazione di fattibilità dei siti, selezione dei siti e reclutamento di pazienti per gli studi clinici.
La Malattia di Huntington (MH) è una rara malattia genetica neurodegenerativa che è causata da una mutazione di un singolo gene; ciascun figlio di un genitore affetto dalla MH ha un rischio del 50% di ereditare il gene mutato e di sviluppare prima o poi la malattia. I sintomi includono disturbi motori, comportamentali e cognitivi, che insorgono solitamente in età adulta.
Ci sono terapie che possono alleviare alcuni dei sintomi legati alla MH e migliorare la qualità di vita dei pazienti con MH e delle loro famiglie. I gruppi di lavoro dell’EHDN hanno sviluppato le linee guida per le migliori pratiche cliniche per la MH, e il Comitato per il Miglioramento delle Cure, parte di Enroll-HD, sta raccogliendo informazioni sulle pratiche cliniche per la MH in tutto il mondo.